TARGET AUDIENCE
This educational activity is intended for members of the hematology care team, including physicians, advanced practice providers, pharmacists, and other specialists who treat patients with hemophilia.

PROGRAM OVERVIEW
This session will explore how new and emerging therapies for hemophilia can address the many unmet needs of patients. The event will feature expert presentations and panel discussions with two hemophilia treatment specialists and three representatives of the hemophilia care team: a community-based physician, a hemophilia nurse, and a patient with hemophilia.

The content is designed to address common questions, concerns, and insights from various perspectives within the hemophilia community, making the discussion relevant to current practices and advancements in the field.

Upon completion of this activity, the learners should be able to:

• Utilize patient needs and preferences to evaluate potential unmet needs of patients with hemophilia
• Compare the clinical profiles of novel and emerging therapies for hemophilia
• Assess how new and emerging treatments impact the individualization of treatment for patients with hemophilia

Stacy E. Croteau, MD, MMS (Co-chair)
Medical Director, Boston Hemophilia Center
Assistant Professor of Pediatrics
Harvard Medical School
Boston, MA

Guy Young, MD (Co-chair)
Director, Hemostasis and Thrombosis Program
Attending Physician; Hematology, Oncology, and Blood and Marrow Transplantation
Investigator, Hematology-Oncology
Children’s Hospital Los Angeles
Los Angeles, CA

Jennifer Maahs, RN, PNP, MSN
Hemophilia Nurse Practitioner
Director of Clinical Care Operations
Indiana Hemophilia & Thrombosis Center, Inc
Indianapolis, IN

Jenny McDaniel, MD
Pediatric Hematologist and Oncologist
Novant Health Hemby Children's Hospital
Charlotte, NC

Cole Kruse
Person living with hemophilia
Indianapolis, IN

In support of improving patient care, this activity has been planned and implemented by The France Foundation. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians: The France Foundation designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The France Foundation designates this activity for 1.50 nursing contact hours.

Physician Assistants: The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until December 19, 2025. PAs should only claim credit commensurate with the extent of their participation.

Pharmacists: This knowledge-based activity, UAN UAN JA0007204-0000-24-096-H01-P qualifies for 1.50 contact hours (0.15 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

This activity is supported by an independent medical educational grant from Sanofi.

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.